AMBU B Ambu A/S Class B

Grant of Performance Share Units and reporting of transactions in accordance with Article 19 of the Market Abuse Regulation

Grant of Performance Share Units and reporting of transactions in accordance with Article 19 of the Market Abuse Regulation

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023. 55,956 of the PSUs have been granted to the Executive Management and 142,916 of the PSUs have been granted to other key employees.

The LTIP covers the financial year 2022/23, and the final allocation of PSUs will be within the range of 0-200% of the initial grant, subject to the actual achievement of EBIT-% and organic revenue growth for the fiscal year 2022/23.

The PSUs are granted free and subject to achievement of the KPIs mentioned above. Each PSU will at vesting, on 1 January 2026, be converted to one B share in Ambu A/S subject to the terms of the LTIP.

The value of the PSUs will, at the time of vesting, be capped at four times the annual base salary of the individual participant measured at the time of the grant.

The share price used for calculating the number of PSUs has been the average share price as of the day of the annual general meeting in Ambu A/S in December 2022 and the following four trading days (14-20 December 2022).





Contacts

Investors

Nicolai Thomsen, Director, Investor Relations, /

Media

Tine Bjørn Schmidt, Head of Corporate Communications, ,

Ambu A/S, Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: , CVR no.: 63 64 49 19,

Attachment



EN
28/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch